US 12,084,641 B2
System for producing cultivated meats, tissues and associated products from cells
Po San Mario Chin, Hong Kong (CN); Kai Yi Carrie Chan, Hong Kong (CN); Chuen Wai Li, Hong Kong (CN); and Tim Spitters, Hong Kong (CN)
Assigned to AVANT MEATS COMPANY LIMITED, Hong Kong (CN)
Filed by Avant Meats Company Limited, Hong Kong (CN)
Filed on Aug. 5, 2021, as Appl. No. 17/395,452.
Application 17/395,452 is a continuation of application No. PCT/IB2020/061257, filed on Nov. 30, 2020.
Claims priority of provisional application 62/942,568, filed on Dec. 2, 2019.
Prior Publication US 2022/0025310 A1, Jan. 27, 2022
Int. Cl. C12M 1/00 (2006.01); A23L 13/00 (2016.01); A23L 17/00 (2016.01); C12M 3/00 (2006.01); C12N 5/071 (2010.01); C12N 5/074 (2010.01); C12N 5/077 (2010.01); C12N 5/0775 (2010.01); C12N 15/113 (2010.01)
CPC C12M 21/08 (2013.01) [A23L 13/00 (2016.08); A23L 17/00 (2016.08); C12M 29/04 (2013.01); C12N 5/0652 (2013.01); C12N 5/0656 (2013.01); C12N 5/0662 (2013.01); C12N 5/0679 (2013.01); C12N 5/0696 (2013.01); C12N 5/0697 (2013.01); C12N 15/113 (2013.01); A23V 2002/00 (2013.01); C12N 2310/141 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/2311 (2013.01); C12N 2501/33 (2013.01); C12N 2501/998 (2013.01); C12N 2510/00 (2013.01); C12N 2513/00 (2013.01); C12N 2531/00 (2013.01); C12N 2533/74 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A system for in vitro meat production comprising:
at least one bioreactor, wherein the at least one bioreactor comprises a sterile bioreactor configured to hold a fluid and at least one type of cells to form tissue, wherein the sterile bioreactor comprises a second solid phase support separated from a first solid phase support by a mesh, wherein the second solid phase support is configured to contain bioengineered cells configured to secrete nutrients, growth factors, and cytokines for bioengineered cells growing on the second solid phase support in situ, wherein the second solid phase support is further configured to physically separate the bioengineered cells from at least one type of cells on the first solid phase support;
a dialysis device comprising a dialysis membrane configured to replenish nutrients to the cells and remove metabolic waste from the sterile bioreactor to dialysate;
a fresh medium device connected to the dialysis unit device and configured to supply the dialysate to the dialysis device; and
a waste removal device connected to the fresh medium device and configured to remove the metabolic waste from the dialysate, wherein the waste removal device is physically separated from the sterile bioreactor and the fresh medium device;
wherein the dialysate comprises nutrients for the cells,
wherein the metabolic waste comprises ammonia and lactate,
wherein the waste removal device comprises a first biocatalyst configured to breakdown ammonia,
wherein the waste removal device comprises a second biocatalyst configured to breakdown lactate to pyruvate, thereby generating fresh carbon sources to promote cell growth in the sterile bioreactor,
wherein the sterile bioreactor, the dialysis device, the fresh medium device and the waste removal device are detachably connected to each other and connected to the system via aseptic connectors.